ZLNA ZELLUNA ASA

Zelluna ASA – Annual General Meeting held on April 29, 2025

Zelluna ASA – Annual General Meeting held on April 29, 2025

Oslo, April 29, 2025: Zelluna ASA held its annual general meeting today April 29, 2025. All the matters on the agenda were approved.

The minutes from the meeting are enclosed and available at the company’s website.

For further information, please see or contact:

Anders Tuv, Chairman of the Board of Directors of Zelluna ASA

Email: 

Phone:

Namir Hassan, CEO, Zelluna ASA

Email: 

Phone:

Hans Vassgård Eid, CFO, Zelluna ASA

Email: 

Phone:

Attachment



EN
29/04/2025

Underlying

ZLNAZELLUNA ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZELLUNA ASA

 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA: Invitation to First Quarter 2025 results webcast presenta...

Zelluna ASA: Invitation to First Quarter 2025 results webcast presentation Oslo, Norway, 30 April 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, invites to a webcast presentation of its first quarter 2025 results, on Thursday, May 8, 2025. The presentation can be followed as a live webcast accessed through a link on at 09:00 CET on Thursday, May 8, 2025. The webcast presentation will be available on the Zelluna website, and it will be possible to post questions during the presenta...

April 30, 2025 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA – Annual General Meeting held on April 29, 2025

Zelluna ASA – Annual General Meeting held on April 29, 2025 Oslo, April 29, 2025: Zelluna ASA held its annual general meeting today April 29, 2025. All the matters on the agenda were approved. The minutes from the meeting are enclosed and available at the company’s website. For further information, please see or contact: Anders Tuv, Chairman of the Board of Directors of Zelluna ASAEmail: Phone: Namir Hassan, CEO, Zelluna ASAEmail: Phone: Hans Vassgård Eid, CFO, Zelluna ASAEmail: Phone: Attachment

April 29, 2025 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna Reaches Major Milestone with Manufacturing Process Established...

Zelluna Reaches Major Milestone with Manufacturing Process Established in Preparation for Clinical Entry of ZI-MA4-1, its Novel TCR-NK Therapy Targeting Solid Tumours Oslo, Norway, 22 April 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, has successfully developed, scaled and automated its proprietary manufacturing process for its TCR-NK cell therapies. This milestone represents a major advancement in the Company’s preparation for clinical entry to provide life-changing, innovative t...

April 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch